Literature DB >> 28924599

Esophageal seeding after endoscopic ultrasound-guided fine-needle aspiration of a mediastinal tumor.

Kensuke Yokoyama1, Jun Ushio1, Norikatsu Numao1, Kiichi Tamada1, Noriyoshi Fukushima2, Alan Kawarai Lefor3, Hironori Yamamoto1.   

Abstract

Background and study aims  Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is rare. A 53-year-old man underwent transesophageal EUS-FNA for diagnosis of a 6-cm mass in the mediastinum as seen by computed tomography (CT). Four weeks later, repeat CT scan revealed a mass in the esophageal wall. Upper gastrointestinal endoscopy confirmed a lesion in the mid-esophagus, which was biopsied and found to be consistent with needle tract seeding after EUS-FNA. Tumor seeding in the gastrointestinal wall or peritoneum after EUS-FNA is rare, but may adversely affect the prognosis. Indications for EUS-FNA must be carefully considered.

Entities:  

Year:  2017        PMID: 28924599      PMCID: PMC5597930          DOI: 10.1055/s-0043-114662

Source DB:  PubMed          Journal:  Endosc Int Open        ISSN: 2196-9736


Introduction

Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful technique to obtain specimens for histopathologic examination. However, there is a small risk of tumor cell seeding along the needle track or within the peritoneum caused by EUS-FNA 1 2 . We report needle track seeding following EUS-FNA in a patient with a mediastinal tumor.

Case Report

The patient was a 53-year-old man who presented with hoarseness. Chest computed tomography (CT) revealed a 6-cm mass in the mediastinum ( Fig. 1 ). EUS showed a heterogeneous, septated tumor. Transesophageal EUS-FNA was performed (  Fig. 2a, b ). Three passes were made with a 22-gauge needle (Olympus Medical Systems, Tokyo, Japan). During the second pass, necrotic tissue was obtained. No immediate adverse events developed after the EUS-FNA. Pathology showed carcinoma with embryonal features ( Fig. 2c, d, e ).
Fig. 1

 Computed tomography (CT) scan findings. a , b CT scan revealed a 6-cm mediastinal mass. c , d Four weeks after endoscopic ultrasound-guided fine-needle aspiration, repeat CT scan revealed a mass in the esophageal wall.

Fig. 2 

Endoscopic ultrasound findings and pathologic findings of biopsy specimens. a Endoscopic ultrasound showed a tumor with a heterogeneous appearance and a septum. b Endoscopic ultrasound-guided fine-needle aspiration was performed with a 22-gauge needle. c The biopsy specimen from the tumor showed tumor cells and necrotic tissue. (hematoxylin-eosin, × 4). d Tumor cells show a papillary pattern. Nuclei are overlaid and cell polarity is lost. e Cells stain positive for AFP ( × 4).

Computed tomography (CT) scan findings. a , b CT scan revealed a 6-cm mediastinal mass. c , d Four weeks after endoscopic ultrasound-guided fine-needle aspiration, repeat CT scan revealed a mass in the esophageal wall. Endoscopic ultrasound findings and pathologic findings of biopsy specimens. a Endoscopic ultrasound showed a tumor with a heterogeneous appearance and a septum. b Endoscopic ultrasound-guided fine-needle aspiration was performed with a 22-gauge needle. c The biopsy specimen from the tumor showed tumor cells and necrotic tissue. (hematoxylin-eosin, × 4). d Tumor cells show a papillary pattern. Nuclei are overlaid and cell polarity is lost. e Cells stain positive for AFP ( × 4). Two weeks after the EUS-FNA, the patient presented with mediastinitis. Symptoms improved with medical therapy. Two weeks later, a repeat CT scan showed a mass in the esophageal wall. Upper gastrointestinal endoscopy showed a protruding lesion in the middle esophagus ( Fig. 3 ), which was biopsied using forceps and confirmed to be histologically similar to the mediastinal mass. This was believed to be consistent with needle tract seeding from the EUS-FNA. Tumor resection was not performed because the mass was felt to be technically unresectable, in part due to the tumor seeding. Chemotherapy was administered and the patient died less than 2 years later.
Fig. 3

 Endoscopic findings. a Upper gastrointestinal endoscopy showed a mass effect in the middle esophagus. b Four weeks after endoscopic ultrasound-guided fine-needle aspiration, a protruding lesion was seen in the middle esophagus

Endoscopic findings. a Upper gastrointestinal endoscopy showed a mass effect in the middle esophagus. b Four weeks after endoscopic ultrasound-guided fine-needle aspiration, a protruding lesion was seen in the middle esophagus

Discussion

This case underscores the potential risk of needle tract seeding after EUS-FNA. In this patient, the location of tumor seeding corresponded to the entry point of the EUS-FNA. The endoscopic unusual appearance of mushroom-shaped tumor protruding from the FNA puncture site was suggestive of seeding as spontaneous direct tumor invasion would be expected to appear as a flat elevation. In addition, the tumor became mucosally based. We believe this is the reason for the rapid development of seeding. The tumor seeding also might have been associated with the post-FNA mediastinitis. The literature from 2003 to 2016 contains reports on only 14 previous patients with needle tract seeding to gastrointestinal tract wall by a malignancy following EUS-FNA (  Table 1 ). Needle size, number of passes, needle movement during puncture, suction, and characteristics of the tumor, might be factors in tumor seeding 3 . According to previous reports, the number of needle passes and tumor characteristics (poorly differentiated or cystic tumor) are considered to be risk factors 2 . Interestingly, needle size was not associated with seeding. In this patient, we speculate that multiple needle passes and tumor characteristics (a poorly differentiated and cystic tumor) may have contributed to development of seeding. Although EUS showed the lesion to be solid, the aspirate showed an abundance of necrotic tissue. We speculated the tumor had a fluid component similar to a cystic tumor.

Summary of previous reports of endoscopic ultrasound-guided fine-needle aspiration seeding.

No. Author year Aspiration site Pathological diagnosis Seeding site Needle size Passes Interval from EUS-FNA until identification of seeding
 1Hirooka, 2003Pancreatic body massAdenocarcinoma (IPMC)Posterior gastric wall (and peritoneal seeding)22G310 days
 2Shah, 2004Perigastric lymph nodeMelanomaPosterior gastric wall22G16 months
 3Paquin, 2005Pancreatic tail cancerAdenocarcinomaPosterior gastric wall22G516 months
 4Doi, 2008Lymph node metastasis of gastric cancerAdenocarcinomaEsophageal wall19G118 months
 5Ashmed, 2011Cystic mass in the pancreatic bodyAdenocarcinomaGastric wall of antrum and bodyUnknownMultiple4 years
 6Chong, 2011Pancreatic tail cancerAdenocarcinomaPosterior gastric wall of body22G22 years
 7Katanuma, 2012Pancreatic body cancerAdenocarcinomaPosterior gastric wall of upper body22G422 months
 8Anderson, 2013Celiac lymph node (and pancreatic head mass)AdenocarcinomaGastroesophageal junctionUnknownUnknownUnknown
 9Minaga, 2015Pancreatic body cancerAdenocarcinomaPosterior gastric wall22G38 months
10Sakurada, 2015Pancreatic body cancerAdenosquamous carcinomaPosterior gastric wall22GUnknown19 months
11Tomonari, 2015Pancreatic body cancerAdenocarcinomaPosterior gastric wall22G28 months
12Iida, 2016Pancreatic body cancerAdenocarcinomaPosterior gastric wall22G36 months
13Kita, 2016Pancreatic body-tail cancerAdenocarcinomaPosterior gastric wall22G27 months
14Yamabe, 2016Pancreatic mass beside cystic lesionsAdenocarcinoma (IPMC)Posterior gastric wall25GUnknown3 months
15Our CaseMediastinal tumorEmbryonal adenocarcinomaEsophageal wall22G34 weeks

IPMC, intraductal papillary mucinous adenocarcinoma

IPMC, intraductal papillary mucinous adenocarcinoma Peritoneal dissemination has been reported more frequently than needle tract seeding. The exact etiology is unknown but once a patient suffers needle tract seeding, the prognosis is worse.

Conclusion

In conclusion, in patients who have lesions that are surgically resectable for curative intent, we must carefully consider appropriate indications for performing EUS-FNA and inform these individuals about the potential for esophageal seeding, which is rare.
  10 in total

1.  Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination.

Authors:  Yoshiki Hirooka; Hidemi Goto; Akihiro Itoh; Senju Hashimoto; Katsushi Niwa; Hideki Ishikawa; Naoto Okada; Terutomo Itoh; Hiroki Kawashima
Journal:  J Gastroenterol Hepatol       Date:  2003-11       Impact factor: 4.029

2.  Melanoma seeding of an EUS-guided fine needle track.

Authors:  Janak N Shah; Douglas Fraker; DuPont Guerry; Michael Feldman; Michael L Kochman
Journal:  Gastrointest Endosc       Date:  2004-06       Impact factor: 9.427

3.  Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia.

Authors:  Andre Chong; Kannan Venugopal; Dev Segarajasingam; Dean Lisewski
Journal:  Gastrointest Endosc       Date:  2011-10       Impact factor: 9.427

4.  Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas.

Authors:  A Katanuma; H Maguchi; S Hashigo; M Kaneko; T Kin; K Yane; R Kato; S Kato; R Harada; M Osanai; K Takahashi; T Shinohara; T Itoi
Journal:  Endoscopy       Date:  2012-05-23       Impact factor: 10.093

5.  A case of EUS-guided FNA-related pancreatic cancer metastasis to the stomach.

Authors:  Kashif Ahmed; Jeffrey J Sussman; Jiang Wang; Nathan Schmulewitz
Journal:  Gastrointest Endosc       Date:  2010-12-18       Impact factor: 9.427

6.  A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma.

Authors:  Sarto C Paquin; Gilles Gariépy; Luigi Lepanto; Raymond Bourdages; Ginette Raymond; Anand V Sahai
Journal:  Gastrointest Endosc       Date:  2005-04       Impact factor: 9.427

7.  Needle tract implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal lymphadenopathy.

Authors:  Shinpei Doi; Ichiro Yasuda; Takuji Iwashita; Takashi Ibuka; Hideki Fukushima; Hiroshi Araki; Yoshinobu Hirose; Hisataka Moriwaki
Journal:  Gastrointest Endosc       Date:  2008-02-14       Impact factor: 9.427

8.  Surgically resected needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration in pancreatic cancer.

Authors:  Kosuke Minaga; Masayuki Kitano; Yukitaka Yamashita
Journal:  J Hepatobiliary Pancreat Sci       Date:  2015-06-17       Impact factor: 7.027

9.  Tumor seeding following endoscopic ultrasonography-guided fine-needle aspiration of a celiac lymph node.

Authors:  Bradley Anderson; Jaswinder Singh; Syed F Jafri
Journal:  Dig Endosc       Date:  2013-03-13       Impact factor: 7.559

10.  Resected tumor seeding in stomach wall due to endoscopic ultrasonography-guided fine needle aspiration of pancreatic adenocarcinoma.

Authors:  Akiko Tomonari; Akio Katanuma; Tomoaki Matsumori; Hajime Yamazaki; Itsuki Sano; Ryuki Minami; Manabu Sen-yo; Satoshi Ikarashi; Toshifumi Kin; Kei Yane; Kuniyuki Takahashi; Toshiya Shinohara; Hiroyuki Maguchi
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

  10 in total
  3 in total

Review 1.  Underwater versus conventional endoscopic mucosal resection for colorectal lesions: a systematic review and meta-analysis.

Authors:  Rajat Garg; Amandeep Singh; Babu P Mohan; Gautam Mankaney; Miguel Regueiro; Prabhleen Chahal
Journal:  Endosc Int Open       Date:  2020-11-27

2.  Fine Needle Aspiration Cytology (FNAC) for Chinese Patients With Acral and Cutaneous Melanoma: Accuracy and Safety Analysis From a Single Institution.

Authors:  Lingge Yang; Wei Sun; Yu Xu; Xun Zhang; Shengping Wang; Chunmeng Wang; Yong Chen
Journal:  Front Oncol       Date:  2020-10-19       Impact factor: 6.244

Review 3.  Overlooked risk for needle tract seeding following endoscopic ultrasound-guided minimally invasive tissue acquisition.

Authors:  Ruo-Yu Gao; Ben-Hua Wu; Xin-Ying Shen; Tie-Li Peng; De-Feng Li; Cheng Wei; Zhi-Chao Yu; Ming-Han Luo; Feng Xiong; Li-Sheng Wang; Jun Yao
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.